Hemrajani Rekha's most recent trade in MaxCyte Inc was a trade of 10,684 Common Stock done at an average price of $2.1 . Disclosure was reported to the exchange on June 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MaxCyte Inc | Rekha Hemrajani | Director | Sale of securities on an exchange or to another person at price $ 2.09 per share. | 25 Jun 2025 | 10,684 | 39,893 | - | 2.1 | 22,378 | Common Stock |
| MaxCyte Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 50,790 | 50,790 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 29,210 | 50,577 | - | 0 | Common Stock | |
| BioAge Labs Inc. | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 40,400 | 40,400 | - | - | Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Hemrajani Rekha | Director | Purchase of securities on an exchange or from another person at price $ 1.55 per share. | 02 Dec 2024 | 30,000 | 33,000 | - | 1.5 | 46,404 | Common Stock |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 20,200 | 20,200 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 40,701 | 40,701 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 21,367 | 21,367 | - | 0 | Common Stock | |
| BioAge Labs Inc. | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 28,497 | 28,497 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc. | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc. | Rekha Hemrajani | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 17 Apr 2024 | 3,000 | 3,000 | - | 18 | 54,000 | Common Stock |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 20,200 | 20,200 | - | - | Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 12,004 | 12,004 | - | - | Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 12,004 | 12,004 | - | - | Stock Option (right to buy) |